Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2012-000844-85 | EudraCT Number | EudraCT |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To investigate the pharmacokinetics and pharmacodynamics of BI 135585 XX following single dose administration.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| BI 135585 XX | Experimental | one single dose |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BI 135585 XX | Drug | one single dose |
|
| Measure | Description | Time Frame |
|---|---|---|
| Cmax (maximum measured concentration of the analyte in plasma) | up to 4 days postdose | |
| AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point) | up to 4 days postdose |
| Measure | Description | Time Frame |
|---|---|---|
| AUC0-8 of BI 135585 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) | up to 4 days postdose |
Not provided
Inclusion criteria:
Exclusion criteria:
1. Any relevant deviation from healthy conditions
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Boehringer Ingelheim | Boehringer Ingelheim | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| 1283.34.1 Boehringer Ingelheim Investigational Site | Neuss | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided